Last reviewed · How we verify
Azithromycin at Baseline
At a glance
| Generic name | Azithromycin at Baseline |
|---|---|
| Sponsor | University of California, San Francisco |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis (NA)
- Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease (PHASE2)
- Sanitation, Water, and Instruction in Face-washing for Trachoma I/II (PHASE3)
- Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM (PHASE4)
- Vitality in Infants Via Azithromycin for Neonates Trial (PHASE4)
- Combined Diagnostic Approach for Refractory Mycoplasma Pneumonia in Children (NA)
- A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea (PHASE3)
- Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azithromycin at Baseline CI brief — competitive landscape report
- Azithromycin at Baseline updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI